Company Overview of Iroko Pharmaceuticals Inc.
Iroko Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the development and commercialization of nonsteroidal anti-inflammatory drug therapeutics for patients to moderate acute and chronic pain. It provides Indocin for the treatment of rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute painful shoulder, and acute gouty arthritis; and Aldomet to treat hypertension. The company’s products under development include Zorvolex, a formulation of diclofenac to treat acute pain in adult patients, as well as completed the Phase III clinical trials for the treatment of osteoarthritis pain; Tiforbex, a formulation of indomethacin that has completed the Phase III clini...
One Kew Place
150 Rouse Boulevard
Philadelphia, PA 19112
Founded in 2012
Key Executives for Iroko Pharmaceuticals Inc.
Executive Chairman of the Board and Chief Executive Officer
Senior Vice President and Chief Financial Officer
Senior Vice President and General Counsel
Senior Vice President and Chief Medical Officer
Senior Vice President of Corporate Development and Alliance Management
Compensation as of Fiscal Year 2015.
Iroko Pharmaceuticals Inc. Key Developments
Iroko Pharmaceuticals Inc. Enters into Licensing Agreement with Laboratorios Saval S.A
Jul 15 15
Iroko Pharmaceuticals Inc. announced that it has entered into a licensing agreement with LABORATORIOS SAVAL S.A. for the exclusive rights to market and sell ZORVOLEX® (diclofenac) capsules, in an additional five countries in South America. LABORATORIOS SAVAL S.A. will be responsible for obtaining regulatory and pricing approval as well as provide marketing and distribution in Bolivia, Chile, Ecuador, Paraguay and Peru.
Iroko Pharmaceuticals Inc. Announces First International Launch of ZORVOLEX
May 14 15
Iroko Pharmaceuticals Inc. announced that ZORVOLEX (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), is now available in 18 mg and 35 mg dosage strengths by prescription in Lebanon. ZORVOLEX was approved by the Republic of Lebanon Ministry of Public Health (MOPH) as a new chemical entity in December 2014 for the treatment of mild to moderate acute pain in adults and osteoarthritis pain. ZORVOLEX is approved by the U.S. Food and Drug Administration (FDA) for the management of mild to moderate acute and osteoarthritis pain, and is available at pharmacies across the United States. Iroko Pharmaceuticals, LLC, an affiliate of Iroko Pharmaceuticals Inc., will continue to retain all marketing rights to ZORVOLEX in the U.S. ZORVOLEX was developed to align with recommendations from FDA and several professional medical organizations that NSAIDs be used at the lowest effective dose for the shortest possible duration consistent with individual patient treatment goals. ZORVOLEX is the first FDA-approved low dose NSAID developed using proprietary SoluMatrix Fine Particle Technology and is now available by prescription. ZORVOLEX contains diclofenac as submicron particles that are approximately 10 times smaller than their original size. The reduction in particle size provides an increased surface area, leading to faster dissolution.
Iroko Pharmaceuticals Inc. Announces Additional International Licensing Agreement for ZORVOLEX
May 6 15
Iroko Pharmaceuticals Inc. announced the initiation of a licensing agreement with Litha Pharma Proprietary Limited for the exclusive rights to market and sell ZORVOLEX (diclofenac) capsules in specified countries in East and Southern Africa. Litha will be responsible for obtaining regulatory and pricing approval as well as provide marketing and distribution in countries including Angola, Botswana, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Republic of South Africa, Seychelles, Swaziland, Tanzania and Zambia. ZORVOLEX is approved by the United States Food and Drug Administration (FDA) for the management of mild to moderate acute pain and osteoarthritis pain, and is available at pharmacies across the United States. ZORVOLEX was also recently approved by the Republic of Lebanon Ministry of Public Health (MOPH) for these indications.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|